Sinovac COVID-19 vaccine safe and effective in children as young as three – Lancet study

CoronaVac, the coronavirus disease jab developed in China by the Sinovac Biotechcompany, was found to be safe and effective in children and adolescents, according to a study published in leading medical journal The Lancet.

Two doses of the vaccine, given 28 days apart, produce a strong antibody response among those aged between three and 17.

Chinese researchers conducted a randomized, double-blind, controlled phase 1/2 clinical trial in Zanhuang County, China. The vaccine was given to more than 500 healthy children and adolescents, 96 percent of whom developed COVID-19 antibodies.

The majority of adverse effects were either mild or moderate, researchers said, and were most likely to be a pain at the injection site.

The general manager of Sinovac said, “We will further carry out large-scale, multi-ethnic population studies in order to provide valuable data for immunization strategies for children and adolescents.”

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.